Skip to main content
. 2021 Jun 10;9(6):e002508. doi: 10.1136/jitc-2021-002508

Figure 2.

Figure 2

MSNs resensitize tumors to αPD-1 through CTLs. (A) Heatmap showing the proportion of tumor-infiltrating CD8+ T cells, NKs, DCs, M-MDSCs, macrophages, CD4+ T cells and G-MDSCs in the Tme after indicated treatments. (B) Scheme of tumor therapy in T cell-deficiency Rag1-/- mice and T cell-regained mice by transferring. (C) Growth of B2m-sgRNA B16F10 tumors in Rag1-/- mice after indicated treatments. (D) Growth of B16F10-OVA tumors in Rag1-/- mice with adoptive transfer of OT-1 CTLs. Error bars represent mean±SEM (n>5 per group in (C, D)). P value was calculated by unpaired Student’s t-test (*P<0.05, **p<0.01, ***p<0.001). CTLs, cytotoxic T-lymphocytes; DCs, dendritic cells; G-MDSCs, granulocytic myeloid-derived suppressor cells; M-MDSCs, monocytic MDSCs; MSNs, mesoporous silica nanoparticles; NKs, natural killer; OVA, ovalbumin; PD-1, programmed cell death protein 1.